Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates

被引:32
|
作者
Tramper-Stranders, G. A. [1 ]
van der Ent, C. K. [1 ]
Molin, S. [2 ]
Yang, L. [2 ]
Hansen, S. K. [2 ]
Rau, M. H. [2 ]
Ciofu, O. [3 ]
Johansen, H. K. [4 ,5 ]
Wolfs, T. F. W. [6 ]
机构
[1] Wilhelmina Childrens Hosp, Cyst Fibrosis Ctr, Univ Med Ctr Utrecht, Dept Paediat Resp Med, NL-3508 AB Utrecht, Netherlands
[2] Tech Univ Denmark, Infect Microbiol Grp, Ctr Syst Biol, DK-2800 Lyngby, Denmark
[3] Univ Copenhagen, Inst Int Hlth Immunol & Microbiol, Copenhagen, Denmark
[4] Rigshosp, Dept Clin Microbiol, DK-2100 Copenhagen, Denmark
[5] Rigshosp, Danish CF Ctr, DK-2100 Copenhagen, Denmark
[6] Wilhelmina Childrens Hosp, Dept Paediat Infect Dis, Univ Med Ctr Utrecht, NL-3508 AB Utrecht, Netherlands
关键词
Chronic infection; cystic fibrosis; genotyping; Pseudomonas aeruginosa; virulence; III SECRETION; PULMONARY INFECTIONS; GENETIC ADAPTATION; DCTA GENE; COLONIZATION; VIRULENCE; STRAINS; MICROEVOLUTION; INACTIVATION; PATHOGEN;
D O I
10.1111/j.1469-0691.2011.03627.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Clin Microbiol Infect 2012; 18: 567574 Abstract Despite intensive eradication therapy, some CF patients with early Pseudomonas aeruginosa infection rapidly develop a chronic infection. To elucidate factors associated with this persistence, bacterial characteristics of early P. aeruginosa isolates were analysed that were either eradicated rapidly or persisted despite multiple antimicrobial treatments. Eighty-six early infection episodes were studied. First P. aeruginosa isolates from patients with eradication (36) or persistent infection (16) were included; isolates from patients with intermittent infection (34) were omitted from the study. Virulence assays, antimicrobial resistance, cytotoxicity and mutation frequencies were analysed in vitro. P. aeruginosa was genotyped by SNP-array. Transcriptomic profiles of two eradicated and two persistent strains were compared. Nineteen per cent of patients developed persistent infection; 42% achieved eradication. Secretion of virulence factors and mutation frequencies were highly variable among both eradicated and persistent isolates and were not different between the groups. Cytotoxicity was present in 57% of eradicated vs. 100% of persistent isolates (p <0.01). None of the isolates were resistant to antibiotics. The isolates were genotypically highly diverse. Multivariate analysis showed that in vitro determined bacterial characteristics could not predict persistence after first P. aeruginosa infection. Preliminary transcriptomic data showed increased expression of some genes related to a metabolic pathway. The early onset of chronic infection was not associated with (in vitro determined) bacterial characteristics only. Although the persistent isolates were more often cytotoxic, for the individual patient it was not possible to predict the risk of persistence based on bacterial characteristics. Unknown factors such as host-pathogen and pathogen-pathogen interactions should be further explored.
引用
收藏
页码:567 / 574
页数:8
相关论文
共 50 条
  • [31] PILOT STUDY FOR OPTIMIZATION OF SEROLOGIC ANALYSIS TO DETECT INITIAL PSEUDOMONAS AERUGINOSA INFECTION IN CYSTIC FIBROSIS PATIENTS
    Lymp, J.
    Khan, U.
    Anstead, M.
    Langkamp, M.
    Barbieri, J.
    Doering, G.
    Ramsey, B.
    PEDIATRIC PULMONOLOGY, 2011, : 282 - 282
  • [32] Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data
    Wenjie Wang
    Ming-Hui Chen
    Sy Han Chiou
    Hui-Chuan Lai
    Xiaojing Wang
    Jun Yan
    Zhumin Zhang
    BMC Medical Research Methodology, 16
  • [33] Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data
    Wang, Wenjie
    Chen, Ming-Hui
    Chiou, Sy Han
    Lai, Hui-Chuan
    Wang, Xiaojing
    Yan, Jun
    Zhang, Zhumin
    BMC MEDICAL RESEARCH METHODOLOGY, 2016, 16
  • [34] Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients
    Lang, AB
    Horn, MP
    Imboden, MA
    Zuercher, AW
    VACCINE, 2004, 22 : S44 - S48
  • [35] Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis
    Smith, Wynne D.
    Bardin, Emmanuelle
    Cameron, Loren
    Edmondson, Claire L.
    Farrant, Katie V.
    Martin, Isaac
    Murphy, Ronan A.
    Soren, Odel
    Turnbull, Andrew R.
    Wierre-Gore, Natasha
    Alton, Eric W.
    Bundy, Jacob G.
    Bush, Andrew
    Connett, Gary J.
    Faust, Saul N.
    Filloux, Alain
    Freemont, Paul S.
    Jones, Andrew L.
    Takats, Zoltan
    Webb, Jeremy S.
    Williams, Huw D.
    Davies, Jane C.
    FEMS MICROBIOLOGY LETTERS, 2017, 364 (14)
  • [36] Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection
    Pukhalsky, AL
    Kapranov, NI
    Kalashnikova, EA
    Shmarina, GV
    Shabalova, LA
    Kokarovtseva, SN
    Pukhalskaya, DA
    Kashirskaja, NJ
    Simonova, OI
    MEDIATORS OF INFLAMMATION, 1999, 8 (03) : 159 - 167
  • [37] Cross-infection with Pseudomonas aeruginosa among patients with cystic fibrosis
    Agarwal, Gunjan
    Kapil, Arti
    Kabra, Susheel Kumar
    Das, Bimal Kumar
    NATIONAL MEDICAL JOURNAL OF INDIA, 2006, 19 (04): : 236 - 237
  • [38] Detection of Pseudomonas aeruginosa infection in cystic fibrosis patients by eNose technology
    Lammers, Marije
    Kos, Renate
    De Vries, Rianne
    Brinkman, Paul
    Dagelet, J. W. F.
    Rutjes, Niels W.
    Majoor, C. J.
    Terheggen-Lagro, S. W. J.
    Weersink, E. J. M.
    Bos, Lieuwe D. J.
    Sterk, Peter J.
    Maitland-Van Der Zee, Anke-Hilse
    Neerincx, Anne H.
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [39] eNose Technology for Detection of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients
    Lammers, A.
    Kos, R.
    de Vries, R.
    Brinkman, P.
    Dagelet, J. W. F.
    Rutjes, N. W.
    Majoor, C. J.
    Terheggen-Lagro, S. W. J.
    Weersink, E. J. M.
    Bos, L. D. J.
    Sterk, P. J.
    Maitland-van der Zee, A. H.
    Neerincx, A. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [40] Clinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection
    Zidaru, Andrei
    Sofjan, Amelia K.
    Devarajan, Sunjay R.
    Tam, Vincent H.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 29 : 551 - 552